The twins.

Seven months ago, Health Canada approved two semaglutide brands that have never been sold anywhere, by anyone. They are made by Novo Nordisk, and they are Ozempic and Wegovy with new names.

Not versions of. Not inspired by. The same drug, from the same company, in new boxes, sitting in a warehouse that may or may not exist yet.

This week we checked every entry in Health Canada’s database to make sure that was still true. It is. The question worth your four minutes is why.

Meet the twins

On December 22, 2025, Health Canada approved Plosbrio and Poviztra. Plosbrio is Ozempic. Poviztra is Wegovy. Same molecule, same manufacturer, same pens, different names on the label.

A Health Canada spokesperson confirmed the products are identical, and said they “didn’t go through the same review process the generic versions do.” There was nothing new to review.

The timing deserves a second look. Novo’s Canadian data exclusivity on semaglutide died on January 4, 2026, opening the generic era. The twins were approved December 22. Novo had its answer to the generics signed and sealed 13 days before the question officially existed.

Then nothing. Seven months of nothing.

Here is what nothing looks like in the official record. Health Canada’s Drug Product Database gives every launched drug the status Marketed. The twins hold 17 drug identification numbers, six for Plosbrio and eleven for Poviztra. On July 29 we checked all 34 database entries, one by one. Every single one reads Approved, the status of a product that has never been put on sale.

0 of 17

Almost nobody is covering this. The dated record on our timeline is, as far as we can find, the only maintained one. We looked: our July audit of three AI search engines found none that tells this story, and mainstream coverage went quiet in January.

Why they exist

Here is the thing about drug prices in Canada: the sticker on a patented brand is not really the company’s to slash. Brand prices are locked in through public negotiation and regulation, and cutting one is slow, visible, and hard to undo.

So a brand that suddenly needs to fight generics on price has a problem. Mina Tadrous, who studies pharmaceutical policy at the University of Toronto, explained Novo’s solution in January: the company cannot simply lower Ozempic’s price to meet the generics, so a renamed identical product is “a way to kind of bypass that and stay competitive.”

That is the whole trick. Plosbrio and Poviztra are not new drugs. They are a new pricing strategy wearing a new label.

The market they are built to defend is not small. More than one million Canadians are on these medications, per Novo Canada’s own president. Semaglutide brings Novo roughly $2.5 billion a year here, its second-largest market for the molecule. Ozempic is the best-selling drug in the country.

And Novo has told us the plan, in one careful word. In January the company said it was “considering” introducing the twins once generics entered the market. Generics entered the market in May. It is now the end of July.

Why the gun is still holstered

To see the bind, look at the shelf.

the canadian semaglutide shelf, per month; brand and telehealth rows reflect published ranges, our phone verification pending

product	price	status
Wegovy, brand	~$540 CAD	on shelves
Ozempic, brand	~$220 to $310 CAD	on shelves
Generic semaglutide, pharmacy	$88 to $120 CAD	Costco lowest at $88 to $99
Generic semaglutide, telehealth	$149 CAD all-in	Felix, MyRocky
Sevmia, first generic Wegovy	unpublished	approved June 29, not yet stocked
Plosbrio and Poviztra	unpublished	approved December 22, never launched

Now run Novo’s math. Fire the twins and every $540 Wegovy patient who switches becomes a cheaper customer Novo created for itself. Hold fire and the $88 generics eat the cash market anyway. There is no move here that does not cost something, which is usually why a company makes neither.

And the floor is still moving. Under the pCPA framework, public plans reportedly cap generic semaglutide reimbursement near $114 a month while two manufacturers are on market, stepping down to roughly $80 the day a third one lists. Sandoz flagged a June launch. We have not yet confirmed the numbers or whether that third listing has happened, but if it has, the price Novo would be undercutting just fell again.

Two more dates hang over the decision. Sevmia, the first generic Wegovy, is expected on shelves between now and the end of August, and its still-unpublished price will define the number the twins have to beat. And Novo reports H1 results on August 5, before the market opens, the first results covering a quarter with generic semaglutide on Canadian shelves.

Which brings us to the one live detail in seven months of stillness. Plosbrio’s product monograph, the official prescribing document, was revised on May 11. Five months after approval, with no launch and no announcement, someone at Novo updated the paperwork for a product that has never shipped.

Companies do not maintain the documents of products they have abandoned. That is launch paperwork without a launch. Someone is getting ready.

They are waiting for Sevmia’s number. The twins are a pricing weapon, and you do not price your counter before the other side prints theirs.

Launch now and Novo shows its hand to every generic still in the review queue. Launch after Sevmia lists and the twins can land a dollar under a known number, in the one week it matters most.

The seven months of stillness is not indecision. It is an ambush that needs the enemy to move first.

And the calendar helps: no CFO volunteers to explain a self-cannibalizing launch on August 5, the same morning as the first down half-year in company history. Watch the two weeks after earnings.

Watching for

• The DPD tripwire. The day any twin DIN flips from Approved to Marketed in Health Canada’s database, the launch has happened whether Novo announces it or not. We check weekly.
• Sevmia’s price and stocking. The window is now through late August, and the number publishes the moment it exists.
• Novo H1 results, August 5, before the open.

That is the brief. Same time Tuesday.